Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

The approval of the first HIV-1 protease inhibitors (HIV-1 PRIs) marked a fundamental step in the control of AIDS, and this class of agents still represents the mainstay therapy for this illness. Despite the undisputed benefits, the necessary lifelong treatment led to numerous severe side-effects (m...

Descripción completa

Detalles Bibliográficos
Autores principales: Monica, Gabriele La, Lauria, Antonino, Bono, Alessia, Martorana, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200130/
https://www.ncbi.nlm.nih.gov/pubmed/34199858
http://dx.doi.org/10.3390/ijms22116070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200130/
https://www.ncbi.nlm.nih.gov/pubmed/34199858
http://dx.doi.org/10.3390/ijms22116070

Ejemplares similares